^

Science and Environment

Roche, Evotec to develop biomarkers in oncology

-

MANILA, Philippines - Roche and Evotec AG recently announced a collaboration in novel protein-activity based biomarkers for Roche’s oncology drugs under development.

Evotec AG will employ its PhosphoScout platform to discover protein-phosphorylations that predict favorable dosage and efficacy of targeted cancer drugs in patients.

Roche will be responsible for conducting clinical trials as well as assessing the development of companion diagnostics for patient stratification.

“We are very pleased to collaborate with Evotec AG and benefit from the PhosphoScout technology to identify appropriate pharmacodynamics and patient stratification biomarkers,” said Mike Burgess, global head of oncology of Roche Pharma Research and Exploratory Development.

“These biomarkers are core to the development of targeted therapeutics for cancer therapy,” Burgess said.

“Biomarker-based personalized health care has led to a paradigm shift in cancer therapy,” said Dr. Werner Lanthaler, chief executive officer of Evotec AG.

“We are proud to partner Evotec’s novel biomarker concept with Roche, the world leading personalized health care company, and its Pharma Research and Development Organization,” Lanthaler said.

Under the initial three-year term, Roche and Evotec will conduct multiple biomarker programs for therapeutic antibodies or small molecule inhibitors.

BIOMARKER

DEVELOPMENT

DR. WERNER LANTHALER

EVOTEC

LANTHALER

MIKE BURGESS

PHARMA RESEARCH AND DEVELOPMENT ORGANIZATION

ROCHE

ROCHE AND EVOTEC

ROCHE PHARMA RESEARCH AND EXPLORATORY DEVELOPMENT

  • Latest
Latest
Latest
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with